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For Rut and Iris. Knowing I have you makes me sleep better. 
  
  
  
ABSTRACT 
Obstructive sleep apnea (OSA) is a common disorder in both children and adults. In adults, 
OSA is a major health concern because it is highly prevalent and increases the risk for hyper-
tension, cardiovascular disease, and mortality. The primary treatment for adults is continuous 
positive airway pressure (CPAP), but surgery with uvulopalatopharyngoplasty (UPPP) is an 
alternative in selected cases. Although CPAP has been shown to successfully improve a pa-
tient’s respiratory sleep parameters, this treatment only modestly improves their blood pres-
sure. The treatment effect of UPPP in improving blood pressure has been less understood, and 
this effect was evaluated in Paper I. 
Surgery is the primary treatment for children with OSA, and adenotonsillectomy (ATE), the 
removal of the tonsils and adenoid, is the first choice of treatment. While ATE is effective in 
improving quality of life and respiratory sleep parameters, residual OSA after surgery is not 
uncommon, especially in children with obesity or severe OSA. A modified ATE with closure 
of the tonsillar pillars, called adenopharyngoplasty (APP), has been suggested to improve the 
surgical outcome. This surgical method was evaluated in Papers II and III. Although OSA 
occurs frequently in children that are between two and four years of age, there are no random-
ized controlled trials (RCT) evaluating the efficacy of surgery in this population of children; 
therefore, this was studied in Paper IV. 
Randomized controlled trials are the optimal study design to evaluate cause-effect relationships 
between different treatments and outcomes, but there are few RCTs evaluating surgical treat-
ment of OSA. This thesis aims to use RCTs to evaluate surgical treatment of OSA in children 
and adults. 
Paper I evaluated changes in morning blood pressure from an RCT that compared patients 
who received modified UPPP (n = 32) with a control group (n = 33). The control group also 
received surgery six months after their first follow-up. The results showed that UPPP improved 
both systolic and diastolic blood pressure after six months. The results in all operated patients 
also indicated that there still was an improvement in both systolic and diastolic blood pressure 
after 24 months. 
Papers II and III reported on an RCT in children, two to four years of age, with severe OSA. 
The patients were randomly assigned to APP (n = 36) or ATE (n = 47) and had a follow-up 
after six months. Respiratory sleep parameters, which were measured with polysomnography 
(PSG), and quality of life, which was measured with a questionnaire called OSA-18, were eval-
uated in Paper II. This study did not show that APP was more effective than ATE. Postoper-
ative morbidity, such as pain, infection, bleeding, satisfaction with treatment, swallowing, and 
speech, was assessed by a logbook, questionnaire, and medical records. The results, presented 
in Paper III, showed only small differences between the groups, in favor of ATE. The com-
bined results of these studies suggest that ATE should still be considered as the primary treat-
ment for otherwise healthy children with severe OSA. 
Paper IV reported on an RCT in children, two to four years of age, with mild to moderate 
OSA. The patients were randomly assigned to ATE (n = 29) or watchful waiting (n = 31) and 
were evaluated with PSG and the OSA-18 questionnaire after six months. The results showed 
only small differences regarding respiratory sleep parameters, but children with moderate OSA 
showed greater improvement after ATE. There were also large differences in quality of life 
between the groups, which increased more after ATE. These results suggest that children with 
moderate OSA should be considered for early ATE, whereas children with low OSA-18 scores 
and mild OSA might benefit from a period of watchful waiting. 
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1 AIMS 
This thesis aims to evaluate surgical treatment of obstructive sleep apnea (OSA) in children 
and adults. 
Specifically, this thesis evaluates 
- the effect that modified uvulopalatopharyngoplasty has on blood pressure in adult 
patients with OSA (Paper I); 
 
- whether children with severe OSA improved more after adenopharyngoplasty than 
adenotonsillectomy by analyzing polysomnography data and OSA-18 scores (a quality 
of life questionnaire) (Paper II);  
 
- postoperative morbidity (e.g. postoperative pain, bleeding, infection, satisfaction with 
treatment, and impaired speech and swallowing) after adenopharyngoplasty compared 
to adenotonsillectomy (Paper III); and 
 
- whether adenotonsillectomy is more effective than watchful waiting for treating mild 
to moderate OSA in children by analyzing polysomnography data and OSA-18 scores 
(Paper IV). 
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2 INTRODUCTION 
2.1 ADULT OBSTRUCTIVE SLEEP APNEA 
2.1.1 Background 
Obstructive sleep apnea (OSA) is a common type of sleep-disordered breathing that is charac-
terized by partial or complete upper airway obstruction during sleep. The prevalence of this 
disorder is rising and is estimated to be 26%, and around 13% of men and 6% of women are 
diagnosed to have moderate to severe OSA1. However, recent studies have suggested that the 
prevalence of moderate to severe OSA is even higher at 50% in men and 23% in women2. OSA 
is becoming a major health concern due to its high prevalence, its independent association with 
hypertension3,4, and the higher risk it carries for cardiovascular disease and mortality5–8. Un-
treated OSA also results in increased health care costs9. 
 
2.1.2 Etiology and risk factors 
Obstructive sleep apnea is caused by a complete or partial repetitive collapse of the upper air-
way during sleep10. The loss of upper airway patency is multifactorial and cannot be explained 
only by the anatomy of the patient’s upper airway. Poor upper airway muscle function, narrow 
upper airway due to craniofacial and soft tissues structures, low arousal threshold, small lung 
volume, and respiratory instability are all believed to be causative factors of OSA11. 
Unlike in children, the major risk factors for OSA as an adult are not tonsillar or adenoid hy-
pertrophy but obesity and being of the male sex1,12. Other important risk factors are increasing 
age, genetic predisposition, drinking alcohol, smoking and menopause1,11,13–15. 
 
2.1.3 Morbidity 
The recurrent asphyxia, fragmented sleep, increased sympathetic nervous system activity, and 
increased intrathoracic pressure that result from episodes of airway obstruction are associated 
with substantial negative health consequences11. Studies have shown that OSA is an independ-
ent risk factor for hypertension3,4, and the prevalence of OSA is between 30% and 83% among 
patients with hypertension16. There is also a high prevalence of unrecognized OSA among pa-
tients with drug-resistant hypertension17. Furthermore, OSA increases the risk of cardiovascu-
lar diseases, such as congestive heart failure, fatal and non-fatal myocardial infarction, and 
stroke5,7,18. An increased risk for cancer, metabolic disorders, cognitive dysfunction, and all-
cause mortality6,8,19, as well as impaired quality of life (QoL) and a higher risk for motor vehicle 
accidents20,21 have also been reported. 
The connection between OSA and these negative health consequences is complex (Figure 1), 
although, the intermittent hypoxemia is believed to promote oxidative stress, increased sympa-
thetic activation, and systemic and vascular inflammation with endothelial dysfunction. These 
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factors are believed to affect cardiovascular disease, metabolic dysfunction, cognitive impair-
ment and cancer19,22. 
 
Figure 1 Possible explanations for the connection between OSA and negative health consequences. 
 
2.1.4 Diagnosis 
In adults, both a clinical evaluation and an objective sleep study are required to diagnose 
OSA23. Common symptoms of OSA are snoring, apneas, nocturnal choking, restless sleep, and 
excessive daytime sleepiness24. The most common symptom of adult OSA is excessive daytime 
sleepiness, but the severity of sleepiness does not seem to correlate to the severity of OSA25. 
The most widely used questionnaire to assess sleepiness is the Epworth Sleepiness Scale 
(ESS)26, and Functional Outcomes of Sleep Questionnaire (FOSQ) is also frequently used27. 
There are also objective tests to measure sleepiness, such as the multiple sleep latency test 
(MSLT)28 and the Oxford sleep resistance (OSLER)29 test. While questionnaires for screening 
for OSA have also been designed, such as the Stop-Bang Questionnaire, they are not suffi-
ciently reliable to diagnose OSA30. 
2.1.4.1 Polysomnography 
Polysomnography (PSG) is the gold standard method to diagnose adult OSA. PSG is performed 
overnight in a sleep laboratory and measures both sleep stages and respiratory functions. A 
standard PSG includes an electroencephalogram (EEG), electrooculogram (EOG), electrocar-
diogram (ECG), and electromyogram (EMG); monitors oronasal airflow, oxygen saturation, 
respiratory movements of the abdomen and thorax, body position, and transcutaneous carbon 
dioxide; and records audio and video during sleep. These data are used to generate several 
parameters, the most common of which is the apnea-hypopnea index (AHI), which measures 
the number of apneas and hypopneas per hour of sleep. The AHI is scored according to the 
manual of 2012 from American Academy of Sleep Medicine (AASM)31. 
The scoring of apneas and hypopneas is similar in children and adults, but the time for a res-
piratory event in adults is ≥ 10 seconds and in children it is defined as the time equivalent of 
two missed breaths (Figure 2). The AHI in adults includes not only obstructive episodes, but 
• Intermittent 
hypoxemia
• Sleep fragmentation
• Large intrathoracic 
pressure swings
• Oxidative stress
• Sympathetic 
nervous system 
activation
• Hypothalamic-
pituitary-adrenal 
axis activation
• Increased cardiac 
pre- and afterload
• Elevated blood 
pressure
• Metabolic 
dysregulation
• Systemic 
inflammation
• Endothelial 
dysfunction
• Myocardial 
dysfunction
• Hypertension
• Type 2 diabetes
• Coronary heart 
disease
• Cerebrovascular 
disease
• Arrhytmia
• Heart failure
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also mixed and central respiratory events31. The AHI is used to classify the severity of OSA: 
mild OSA, AHI ≥ 5 and < 15; moderate OSA, AHI ≥ 15 and < 30; and severe OSA, AHI ≥ 30. 
Apnea (all criteria must be satisfied) 
• The respiratory event lasts for at least two missed breaths in children, determined by the baseline 
breathing pattern, OR ≥ 10 seconds in adults. 
• The event is associated with a ≥ 90% drop in the airflow signal amplitude. 
• To qualify as an obstructive apnea, the event must be associated with the presence of respiratory effort 
throughout the entire period of absent airflow. 
Hypopnea (all criteria must be satisfied) 
• The event is associated with a ≥ 30% drop in airflow signal amplitude. 
• The respiratory event lasts for at least two missed breaths in children, determined by the baseline 
breathing pattern, OR ≥ 10 seconds in adults. 
• There is a ≥ 3% desaturation, or the event is associated with an arousal. 
Figure 2 Criteria for scoring respiratory events as apneas and hypopneas, according to AASM. 
 
Other common parameters are the oxygen desaturation index (ODI), which is the number of 
desaturations of more than 3% or 4% per hour, respiratory effort-related arousals (RERA), 
respiratory disturbance index (RDI), and lowest oxygen saturation (saturation nadir). 
Polysomnography is expensive and resource demanding, and it is, therefore, not always avail-
able. Polygraphy (PG) is more widely available and allows the patient to perform the sleep 
study at home. However, the true sleep time, arousals, and sleep stages cannot be assessed with 
PG as it lacks EEG, EOG, and EMG. Consequently, true sleep time, some hypopneas, and 
sleep fragmentation are missed by PG, resulting in missed diagnosis of OSA or misdiagnosis 
of its severity. Consequently, it is important to perform PSG on patients that have excessive 
daytime sleepiness, a high clinical suspicion of OSA, and a normal PG32. However, PSG also 
has its limitations, and night-to-night variability has been reported33,34. A second PSG could, 
therefore, be of value if the PSG result is in conflict with the clinical assessment. 
 
2.1.5 Treatment 
2.1.5.1 Continuous positive airway pressure  
Continuous positive airway pressure (CPAP) is a treatment that uses air pressure to keep the 
airway open and is the primary treatment for adult OSA. If accepted, CPAP has a positive effect 
on nocturnal respiratory parameters, excessive daytime sleepiness, and QoL35,36. However, 
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studies have shown that patients have difficulties adhering to CPAP and have reported long-
term compliance of around 50-68%37–39. 
2.1.5.2 Mandibular retaining device  
A mandibular retaining device (MRD) is also a common treatment option and it prevents the 
collapse of the upper airway by repositioning the lower jaw forwards. While studies have 
shown improvements in respiratory parameters and sleepiness, this treatment is not as effective 
as CPAP and is recommended for less severe forms of OSA40. As with CPAP, there are chal-
lenges with patient adherence, and MRDs have a compliance rate around 56-68%41. 
2.1.5.3 Surgery 
Before the introduction of CPAP and MRDs, palate surgery, such as uvulopalatopharyn-
goplasty (UPPP), was the primary therapy for OSA. UPPP enlarges the oropharyngeal airway 
and reduces the collapsibility by adjusting the pharyngeal soft tissue (tonsils, uvula and soft 
palate)42. The efficacy and safety of UPPP have been questioned43,44, but recent studies using 
modified UPPP in a selected group of patients have shown the surgery to be both safe and 
effective to improve respiratory parameters, QoL and sleepiness45–49.  
To select candidates for surgery it is important to assess the pharyngeal anatomy and patient 
obesity. The Friedman staging system is the most common clinical assessment method and is 
based on palate position, tonsil size and body mass index50. It has shown correlations between 
preoperative examination and surgical outcome50,51, but low inter-examiner agreement might 
limit the value of this staging system52. Drug induced sleep endoscopy (DISE) is another tool 
for preoperative evaluation of adult patients with OSA and can be used to assess the level of 
obstruction. DISE evaluates the specific site and character of the upper airway obstruction dur-
ing a pharmacological sleep. Although some studies have indicated a higher surgical success 
rate after DISE53, there is insufficient evidence to claim that this approach leads to a better 
surgical outcome compared to a normal clinical evaluation of the upper airway in fully awake 
patients54,55. 
2.1.5.4 Other treatments 
There are several alternative treatment options for OSA, including weight loss, bariatric sur-
gery, sleep positioning, and upper airway stimulation. Obesity is a major risk factor for OSA, 
and meta-analyses have shown that weight loss through lifestyle changes or bariatric surgery 
can improve OSA parameters56,57. Furthermore, sleeping in the supine position often contrib-
utes to the collapse of the upper airway, so it is generally recommended that OSA patients sleep 
in a lateral position. However, even if patients have primarily positional OSA, studies have 
shown that positional therapy is inferior to CPAP58. Upper airway stimulation, through stimu-
lation of the hypoglossal nerve, has shown promising results in patients with moderate to severe 
OSA and could become an alternative to CPAP59,60. 
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2.1.5.5 Treatment effect on blood pressure 
Hypertension is a known consequence of OSA, but both CPAP and MRDs show only a slight 
improvement in systolic (SBP) and diastolic blood pressure (DBP). Systematic reviews of 
CPAP showed a mean decrease of 2.6 and 2.0 mmHg in SBP and DBP, respectively61,62. A 
systematic review of MRDs had similar results, with a decrease of 2.7 mmHg in both SBP and 
DBP63. While drug resistant hypertension is common in patients with OSA17,64, antihyperten-
sive medication (angiotensin II receptor blocker) is still almost four times more effective than 
CPAP in patients with OSA65.  There are studies that indicate that UPPP can improve blood 
pressure in patients with, but the overall evidence is weak. Randomized controlled trials (RCT) 
evaluating the effect UPPP has on blood pressure and other cardiovascular endpoints are 
needed and have been requested66. In this thesis, the effect of modified UPPP on blood pressure 
was evaluated in Paper I. 
 
2.2 PEDIATRIC OBSTRUCTIVE SLEEP APNEA 
2.2.1 Background 
The prevalence of OSA in the pediatric population ranges from 1% to 6%67–69 and the peak 
prevalence occurs between three and six years of age70. The obstructive episodes lead to recur-
rent asphyxia, fragmented sleep and increased sympathetic nervous system activity71, and are 
associated with numerous morbidities and complications if left untreated72,73. Early diagnosis 
is not only important for the health of the child, but also from a socioeconomic perspective, as 
untreated OSA is associated with increased healthcare costs74,75. 
 
2.2.2 Etiology and risk factors 
As in adults, OSA in children is caused by a narrowing of the upper airway, and the etiology 
of the obstruction is multifactorial72,76. Pediatric OSA is primarily caused by enlarged tonsils 
and adenoid, but neuromuscular factors may also affect the collapsibility of the upper air-
way77,78. Obesity, an increasing health problem, is another major risk factor for OSA79,80. Other 
groups with high risk of OSA include children with neuromuscular disorders81, craniofacial 
abnormalities78, prematurity82, laryngomalacia83, and chromosomal abnormalities, like Down 
syndrome84,85. There are also studies that have suggested an hereditary component to OSA 86,87. 
 
2.2.3 Morbidity 
OSA is associated with a wide array of disorders, such as neurocognitive dysfunction and be-
havioral disturbances, which are characterized by hyperactivity, aggressive behavior, learning 
problems and concentration difficulties88–90. Failure to thrive91, cardiovascular complications 
with systolic and pulmonary hypertension92,93, and increased mortality rates73 have also been 
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reported for pediatric patients with OSA. There is also an association between OSA and 
asthma, and treatment of OSA seems to improve asthma control94. 
 
2.2.4 Diagnosis 
The evaluation of a child with suspected OSA starts with an assessment of symptoms, risk 
factors, and a physical examination. Common nocturnal symptoms of OSA are snoring, apneas, 
restless sleep, enuresis, excessive sweating, and cervical hyperextension. Daytime symptoms 
are more difficult to distinguish and can include mouth breathing, excessive daytime sleepi-
ness, concentration difficulties, hyperactivity, and failure to thrive72,95,96. 
2.2.4.1 Polysomnography  
Clinical evaluation and medical history are not always reliable. As with adults (see chapter 
2.1.4.1), the gold standard for diagnosing pediatric OSA is PSG72,97. Studies have shown a low 
night-to-night variability in children and a single PSG is considered sufficient to diagnose 
OSA72,98. 
In contrast to OSA in adults, an obstructive apnea-hypopnea index (OAHI) is mainly used, and 
this index does not include central or mixed events. The OAHI is used to determine the severity 
of OSA, and the following cut-offs are the most widely used95: mild OSA, OAHI ≥ 1 and < 5; 
moderate OSA, OAHI ≥ 5 and < 10; and severe OSA, OAHI ≥ 10. 
Although PSG is the best available method to diagnose OSA, it is expensive, time consuming 
and not accessible for all patients. Furthermore, there are no strong correlations between PSG 
outcomes and QoL99–102. If PSG is not available, there are other objective methods that might 
help in the diagnosis of OSA, such as PG and nocturnal oximetry72,103. However, these methods 
have limitations in the diagnostic reliability that must be considered104,105. DISE can also be 
used in children, but it is not used in Sweden, and there are no studies that show improved 
surgical outcomes after DISE. However, DISE might be of value to children with persistent 
OSA after surgery106. 
2.2.4.2 OSA-18 Questionnaire 
Numerous questionnaires have been developed to simplify the evaluation of pediatric OSA, 
but they are all limited when it comes to diagnosing OSA107. OSA-18 is the most common 
questionnaire used in Sweden, and, like other questionnaires, it has been shown to be a poor 
predictor of OSA and to evaluate the severity of OSA102,108. Even so, OSA-18 is useful to de-
termine the QoL in pediatric patients with OSA, and to evaluate differences before and after 
surgery109,110. 
The OSA-18 questionnaire consists of 18 questions across five domains: sleep disturbance, 
physical symptoms, emotional distress, daytime function, and caregivers’ concerns (Figure 3). 
Each question is scored on a 7-point Likert scale. Answers are summed to a total OSA-18 score 
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ranging from 18 to 126 points, where higher scores indicate a worse QoL. Scores less than 60 
suggest a mild impact on QoL, scores between 60 and 80 suggest a moderate impact, and scores 
above 80 suggest a severe impact.111 The OSA-18 questionnaire also contains a global rating 
of QoL on a visual analogue scale (VAS QoL) of 0 to 10 points. 
 
Figure 3 The OSA-18 questionnaire. 
 
2.2.5 Treatment 
2.2.5.1 Adenotonsillectomy and adenopharyngoplasty 
Surgery is the primary treatment for pediatric OSA, and adenotonsillectomy (ATE), removal 
of the tonsils and adenoid, is considered the first choice of treatment72,112. ATE has been shown 
OSA-18 Quality of Life Survey 
Evaluation of Sleep-Disordered Breathing 
 
 
Instructions.  For each question below, please circle the number that best describes how often each 
symptom or problem has occurred during the past 4 weeks (or since the last survey if sooner).  Thank you. 
 
 None of the 
time 
Hardly 
any of
the time
A little 
of the 
time 
Some 
of the 
time 
A good 
bit of 
the time 
Most 
of the 
time 
All of 
the 
time 
SLEEP DISTURBANCE 
During the past 4 weeks, how often has your child had… 
       
…loud snoring? 
…breath holding spells or pauses in breathing at night? 
…choking or gasping sounds while asleep? 
…restless sleep or frequent awakenings from sleep? 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
PHYSICAL SUFFERING 
During the past 4 weeks, how often has your child had… 
       
…mouth breathing because of nasal obstruction? 
…frequent colds or upper respiratory infections? 
…nasal discharge or runny nose? 
…difficulty in swallowing foods? 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
EMOTIONAL DISTRESS 
During the past 4 weeks, how often has your child had… 
       
…mood swings or temper tantrums? 
…aggressive or hyperactive behavior? 
…discipline problems? 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
5 
5 
5 
6 
6 
6 
7 
7 
7 
DAYTIME PROBLEMS 
During the past 4 weeks, how often has your child had… 
       
…excessive daytime drowsiness or sleepiness? 
…poor attention span or concentration? 
…difficulty getting out of bed in the morning? 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
5 
5 
5 
6 
6 
6 
7 
7 
7 
CAREGIVER CONCERNS 
During the past 4 weeks, how often have the above problems… 
       
…caused you to worry about your child’s general health? 
…created concern that your child is not getting enough air?
…interfered with your ability to perform daily activities? 
…made you frustrated? 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
 
 
OVERALL, HOW WOULD YOU RATE YOUR CHILD’S QUALITY OF LIFE AS A RESULT OF THE ABOVE PROBLEMS? 
(Circle one number) 
 
x   x x   x x   x x   x x   x x   x 
 
 
          
0 1 2 3 4 5 6 7 8 9 10 
Worse Possible Half-way Between Best Possible 
Quality-of-Life Worst and Best Quality-of-Life 
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to have a positive effect on respiratory sleep parameters, QoL, and patient behavior and has 
also resulted in improved healthcare costs113,114. Even so, residual OSA is reported to occur in 
13% to 75% of children after surgery112,115–118. Risk factors for persistent OSA are severe OSA, 
obesity, and genetic, neurological, and craniofacial disorders115,116,119–121. 
To improve the surgical outcome, alternative methods to ATE have been developed to reduce 
the obstruction of the upper airway. The soft palate and pharyngeal walls are anatomical factors 
involved in the obstruction of the upper airway122,123, and a closure of the tonsillar pillars after 
ATE is believed to enlarge the upper airway. In 2004, Guilleminault et al.124 described that a 
modified adenotonsillectomy with closure of the tonsillar pillars, called adenopharyngoplasty 
(APP) (Figure 4), resulted in a 100% success rate. This was followed by a (RCT) in 2012 by 
Friedman et al.125 between APP (n = 19) and ATE (n = 25). While the results from that study 
were in favor of APP, no significant group differences were observed, and the authors reported 
that the study was underpowered due to a high dropout rate (27%). Further, a non-randomized 
prospective controlled study by Chiu et al.126 in 2013 showed that APP (n = 12) was signifi-
cantly more effective than ATE (n = 12), with a reduction in apnea-hypopnea index (AHI) of 
80% compared to 43%. These studies indicate that APP might be a more effective surgical 
method than ATE, but the overall evidence is weak. In this thesis, APP was evaluated in Papers 
II and III. 
 
 
Figure 4 Left: Adenotonsillectomy (ATE): Removal of tonsils with cold steel technique. Right: Adenopharyngoplasty 
(APP): Closure of the tonsillar pillars after tonsillectomy, with two sutures on each side including fibers of the palatopha-
ryngeus muscle. Reprinted with permission. ã (2018). AMA. All rights reserved. 
 
2.2.5.2 Watchful waiting 
Not all children receive surgery, and, in accordance with some guidelines, children with mild 
OSA are not recommended ATE95,127. Through studies and clinical experience, it is known that 
children with less severe forms of OSA may get better without treatment. For example, a large 
randomized controlled trial known as the Childhood Adenotonsillectomy Trial (CHAT)113 
compared ATE with no treatment in 464 children with OSA. The children were between five 
and nine years of age, had primarily mild to moderate OSA, and the median obstructive apnea-
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hypopnea index (OAHI) was less than 5 in both groups at baseline. The CHAT study reported 
that 46% of the group without treatment achieved normal PSG parameters (defined as OAHI 
< 2) at follow-up, compared to 79% in the group that received ATE. While the difference be-
tween the groups was significant, there seems to be a non-negligible spontaneous improvement 
in the group without treatment. Although ATE is one of the most common surgical procedures, 
there are no RCTs in children between two and four years of age that confirm the benefit of 
surgery compared to no treatment. This study has been requested128 and was evaluated in Paper 
IV. 
2.2.5.3 Other treatment methods 
Alternative treatments for OSA in children include partial tonsillectomy, CPAP, and anti-in-
flammatory agents, such as intranasal steroids and leukotriene antagonists72,129–131. Partial ton-
sillectomy, also called tonsillotomy, is becoming more frequent in Sweden and has shown good 
treatment results129,132. Children seem to return faster to normal activity after tonsillotomy com-
pared to tonsillectomy; nevertheless, the long-term effect and need for repeated surgery is still 
uncertain133. Children with non-severe OSA who receive intranasal steroids and leukotriene 
antagonists have shown improvement in their PSG parameters as well as their QoL134–136. 
CPAP is not a common treatment in Sweden for children with OSA, but it can be an option for 
children with persistent OSA after surgery or when surgery is not recommended (e.g. obesity 
and craniofacial disorders)72. However, as with adults, pediatric patients struggle with poor 
treatment adherence to CPAP137. 
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3 MATERIALS AND METHODS 
3.1 OVERVIEW OF STUDY DESIGNS 
All papers were based on RCTs conducted at the Department of Otorhinolaryngology, Karolin-
ska University Hospital, Stockholm, Sweden. An overview the papers is provided in Table 1. 
 
Table 1 Overview of the papers included in this thesis. 
Paper 
Study 
design 
Population Intervention Comparison Outcome Time 
I. RCT Adults, BMI < 
36, moderate to 
severe OSA 
UPPP No treatment Blood pressure 6 and 24 
months 
II. RCT Children, 2-4 
years, severe 
OSA 
APP ATE Respiratory sleep 
parameters (PSG) 
and Quality of Life 
(OSA-18) 
6 months 
III. RCT Children, 2-4 
years, severe 
OSA 
APP ATE Postoperative mor-
bidity (e.g. pain, 
bleeding, infection, 
satisfaction, swal-
lowing, and speech) 
6 months 
IV. RCT Children, 2-4 
years, mild to 
moderate OSA 
ATE No treatment Respiratory sleep 
parameters (PSG) 
and Quality of Life 
(OSA-18) 
6 months 
Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; RCT, randomized controlled trial; BMI, body 
mass index; OSA, obstructive sleep apnea; UPPP, uvulopalatopharyngoplasty; PSG, polysomnography. 
 
3.2 PAPER I – BLOOD PRESSURE AFTER MODIFIED UVULOPALATO-
PHARYNGOPLASTY 
3.2.1 Design and study population 
This study utilized data from a previous single-center RCT, called Sleep apnea Karolinska 
UPPP (SKUP3)45, that compared adult patients with OSA who received modified UPPP to a 
control group. The primary study was designed to evaluate respiratory sleep parameters using 
PSG. 
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All patients that were referred for UPPP were possible candidates for the study, and the fol-
lowing inclusion criteria were used: over 18 years of age; AHI ≥ 15 events/h of sleep; ESS 
score ≥ 8; expressed daytime sleepiness three times a week or more; BMI < 36 kg/m2; Friedman 
stage I or II50; having failed treatment with MRD and CPAP; and no use of MRD nor CPAP 
three months before the first PSG. The exclusion criteria were: serious cardiopulmonary, psy-
chiatric, or neurological disease; an American Society of Anesthesiologists classification of 
>3; did not want to perform surgery; insufficient knowledge of Swedish; nightshift worker; 
being potentially dangerous in traffic; severe nasal congestion; previous tonsillectomy; and 
Friedman stage III50. Those who experienced severely aggravated OSA symptoms during the 
study were also excluded. 
Ultimately, a total of 65 patients were included in this study (Figure 5) and the primary follow-
up was after six months. The control group received surgery after the initial six months and 
had an additional postoperative follow-up after six months. All patients had a follow-up after 
24 months. Each follow-up included an overnight PSG, and the patient’s blood pressure was 
measured manually the following morning at 6:00 am, directly after awakening, and while the 
patients were lying on their backs. 
The PSG scorers and the nurses, who measured the blood pressure, were blinded for treatment 
allocation. 
 
Figure 5 Flowchart Paper I. Abbreviations: BP, blood pressure; ITT, intention to treat; UPPP, uvulopalatopharyn-
goplasty; PSG, polysomnography. 
Randomization
(n=71)
Baseline Intervention group (n=32)
Available BP data (n=28)
Missing value (n=4)
Baseline Control group (n=33)
Available BP data (n=31)
Missing value (n=2)
Polysomnography (PSG)
Excluded (n=1)
Adjusted BP medication (n=1)
PSG: 6-month follow-up (n=33)
Available BP data (n=33)
Excluded
Patients from a second centre that
deviated from study protocol (n=4)
Did not meet final inclusion criteria
(n=2)
PSG: 2-year postop follow-up (n=52)
Available BP data (n=38)
Missing value (n=3)
Total exluded (n=11)
Drop-out (n=5)
Excluded (n=1)
Started BP medication (n=1)PSG: 6-month postop follow-up (n=28)
Available BP data (n=25)
Missing value (n=1)
Excluded (n=2)
PSG: 6-month postop follow-up (n=32)
Available BP data (n=28)
Missing value (n=1)
Excluded (n=3)
Drop-out (n=8)
Excluded (n=6)
Started BP medication (n=2)
Adjusted BP medication (n=4)
Final inclusion SKUP3
(n=65)
Excluded (n=3)
Started BP	medication (n=2)
Adjusted BP	medication (n=1)
Intervention (delayed UPPP)
Intervention (UPPP)
ITT-analysis
(n=71)
  13 
3.2.2 Intervention 
The surgical method was a modification of the UPPP originally described by Fujita et al.42. 
There were only minor resections of the uvula and soft palate, including tonsillectomy, and the 
surgery was performed with the cold steel technique (Figure 6). 
 
 
Figure 6 Modified uvulopalatopharyngoplasty. (1) Marked excision line laterally to the uvula. (2) Excision of the anterior 
tonsillar pillar 2–3 mm and the mucosa between the pillars. (3) Tonsillectomy with cold steel. (4) Suturing of the soft pal-
atal mucosa. Single sutures lift up the posterior pillar and the palatopharyngeal muscle to the anterior pillar. (5) Amputa-
tion of the uvula leaving approximately 1 cm. (6) Final result. Reprinted with permission. ã (2013). BMJ. All rights re-
served. 
 
3.2.3 Outcome measures 
The UPPP and control group patients’ systolic and diastolic blood pressures were compared 
between the baseline and at the initial six-month follow-up. Additionally, after the control 
group received delayed surgery, blood pressure was evaluated for all operated patients after six 
and 24 months. Correlation tests were also performed in order to compare the blood pressure 
with respiratory sleep parameters (e.g. AHI, ODI and oxygen saturation nadir).  
 
3.2.4 Statistical analyses 
The blood pressure is presented as mean with either standard deviation (SD) or 95% confidence 
interval (CI). Paired and unpaired t-tests were used to analyze blood pressure changes within 
and between the groups. Pearson’s correlation test was used to determine the relationship be-
tween blood pressure and respiratory sleep parameters. All available blood pressure data were 
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included in the analyses, but blood pressure values that may have been affected by changes in 
antihypertensive treatment were excluded from the primary analysis. 
An intention-to-treat (ITT) sensitivity analysis was performed to compare the surgery and con-
trol groups at the six-month follow-up. Missing values and values that might have been affected 
by changes in antihypertensives were imputed as no change from baseline, same as follow-up, 
or, if both values were missing, the mean value for the group at baseline. A sensitivity analysis 
was also performed for all operated patients. Values that may have been affected by changes 
in antihypertensives were imputed as a “worst case scenario” with a value of 250/150. This 
sensitivity analysis was analyzed with the Wilcoxon signed rank test, a non-parametric test. 
 
3.3 PAPERS II and III – ADENOTONSILLECTOMY VS. ADENOPHARYNGO-
PLASTY 
3.3.1 Design and study population 
This study was a blinded RCT with two parallel arms comparing APP and ATE in children 
who were two to four years of age, otherwise healthy, and had severe OSA. All children re-
ferred for OSA to the Otorhinolaryngology department at Karolinska University Hospital, 
Stockholm were offered a PSG. Children who completed the PSG were possible candidates for 
the study and they were offered participation if they met the inclusion criteria (≥ 2 to < 5 years 
of age; history or symptoms of OSA; severe OSA, defined as an OAHI ≥ 10; tonsil hypertrophy 
2–4 according to Brodsky138; and caregivers with sufficient knowledge of Swedish) and exclu-
sion criteria (presence of craniofacial abnormality, cardiopulmonary disease, chromosomal ab-
normality, previous adenotonsillar surgery, neuromuscular disease, or bleeding disorder). Final 
inclusion was determined on the day of operation. 
A study population of at least 44 children was recommended, but a total of 83 children were 
included in order to compensate for limitations in the power analysis and dropouts. The power 
analysis (a level of 0.05 and 90% power) was based on a reduction of 75% in OAHI after 
ATE113,116 and that a further decrease of 10% after APP would be of clinical value. 
The randomization was performed on the day of operation with sealed envelopes, which were 
stratified into two strata (OAHI <30 or OAHI ≥30). The surgeons received sealed envelopes 
with the surgery type and did not meet the children or the caregivers after the operation. The 
caregivers, patients, researchers, and PSG scorer were blinded to surgical method. 
Both groups had a follow-up six months after surgery, during which they were assessed with a 
new PSG. At both baseline and the follow-up, the caregivers answered the OSA-18 question-
naire. Furthermore, a logbook was used to evaluate the patient’s postoperative pain, and an 
additional questionnaire regarding postoperative morbidity was answered at the follow-up. The 
flow of participants is illustrated in Figure 7. 
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Figure 7 Flowchart Paper II and III. Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; OSA, ob-
structive sleep apnea; PSG, polysomnography. 
 
3.3.2 Intervention 
All children were operated on with the cold steel technique. The tonsils were removed by blunt 
extracapsular dissection, and the adenoid was removed with a ring knife. The children in the 
APP group also had their tonsillar pillars lateralized and closed. This was performed with two 
inverted sutures, Monocryl 4/0 (Ethicon, USA), on each side, including fibers of the palatopha-
ryngeus muscle (see Figure 4). All children received locally administrated bupivacaine periop-
eratively, and perioperative hemostasis was obtained with compression and bipolar diathermia. 
Perioperative blood loss was registered by the surgeon. All children were prescribed analgesics 
(paracetamol and ibuprofen) according to a standardized schedule. No antibiotics were given 
peri- or postoperatively. 
 
3.3.3 Outcome measures 
3.3.3.1 Paper II 
The primary outcome was to compare how the OAHI changed after surgery for the children 
who underwent ATE versus APP at the six-month follow-up. Other outcomes included com-
paring for changes in other PSG variables: central AHI, rapid eye movement AHI, ODI (using 
PSG
(n = 203)
ATE
(n = 47)
APP
(n = 36)
Children with symptoms of 
OSA
Dec 2014 - Nov 2016 
Dropouts
Moved abroad (n = 2)
Could not go through with PSG (n = 1)
Declined further participation (n = 3)
Follow-up
PSG (n = 30)
Logbook (n = 25 )
Questionnaire (n = 27)
Excluded
Did not meet inclusion/exclusion criteria 
(n = 81) 
Declined to participate (n = 10)
Other reason (n = 29)
Follow-up
PSG (n = 44)
Logbook (n = 39)
Questionnaire (n = 38)
Randomization
(n = 83)
Dropouts
Could not go through with PSG (n = 1)
Declined further participation (n = 2)
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the ≥ 3% desaturation criteria), RDI, mean oxygen saturation, lowest oxygen saturation level, 
total sleep time, and sleep efficiency. The level of postoperative OAHI (< 1, < 2, < 5, and < 10) 
was analyzed to evaluate the success of surgery. Subgroup analyses were performed for chil-
dren with obesity (BMI z-score ≥ 1.67) and for different levels of preoperative OAHI (≥ 20 
and ≥ 30). 
Furthermore, the data from the OSA-18 questionnaire were used to analyze differences be-
tween the groups for postoperative changes in total symptom score, sleep disturbance index, 
and general health related QoL. The need for repeated surgery because of residual OSA and 
postoperative complications, such as infection and readmission due to bleeding, was also eval-
uated. 
3.3.3.2 Paper III 
All patients received a logbook to record pain level, analgesics given, and food intake for the 
first 10 days after surgery. Pain was assessed three times per day by both the children and the 
caregivers. The children used a standardized self-reporting scale (0–10) called the Faces Pain 
Scale – Revised (FPS-R) (Figure 8). This scale consists of six different faces, is validated for 
children from four years of age, and is recommended by the Pediatric Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials139–141. The caregivers assessed the pain 
from 1–10 by using a visual analogue scale (VAS). The food intake was registered by the care-
givers as amount (less than normal, normal, or more than normal) and texture (liquid, soft, or 
normal). Also, the patient’s weight in kilograms was registered, using the same scale, on the 
first and tenth day after surgery. 
The data retrieved from the logbook were evaluated according to seven different pain-related 
outcomes: (1) first day when the child was pain free (FPS-R = 0); (2) first day when the child 
had FPS-R < 6; (3) first day when the caregiver estimated the child to be free of pain (VAS = 
1); (4) first day when the caregiver estimated the child to have VAS ≤ 5; (5) first day without 
analgesics; (6) first day with normal diet (defined as normal texture in combination with normal 
or more than normal amount); and (7) mean weight change. 
 
 
Figure 8 Faces Pain Scale-Revised (FPS-R). https ://www.iasp-pain. org/fpsr. Copyright © 2001, International Associa-
tion for the Study of Pain®. Reproduced with permission. 
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Postoperative bleeding and infection were assessed by evaluating clinical records and a ques-
tionnaire at the six-month follow-up. Only bleeding that required surgical treatment or read-
mission was defined as postoperative bleeding. Perioperative blood loss was also evaluated. 
Further, the caregivers answered a questionnaire at the six-month postoperative follow-up re-
garding global satisfaction with treatment (yes or no), patient’s speech (improved, unchanged, 
worse, or much worse) and patient’s swallowing (improved, unchanged, worse, or much 
worse). Swallowing and speech data were dichotomized to impaired (worse or much worse) 
and not impaired (improved or unchanged). 
 
3.3.4 Statistical analyses 
3.3.4.1 Paper II 
The primary analysis was per protocol, but an ITT analysis was also performed regarding the 
primary outcome of change in OAHI. Missing values were imputed by the last observation 
carried forward method. The PSG variables were continuous data, and parametric statistical 
tests, including paired and unpaired t-tests, were used to analyze differences within and be-
tween the groups. The results are given as the mean (SD) or as the mean (95% CI). The test of 
proportion was used to compare different levels of surgery success. 
The OSA-18 questionnaire consisted of ordinal data and was analyzed with non-parametric 
tests, including the Wilcoxon signed-rank test within groups and the Mann–Whitney U-test 
between groups. The results are given as the median (interquartile range) or as the median (95% 
CI). 
All data were analyzed with Stata 15 (StataCorp, USA). 
3.3.4.2 Paper III 
The analysis was per protocol. The pain-related outcomes are reported as the median (inter-
quartile range). The group differences were analyzed with log-rank tests (nonparametric) and 
illustrated with Kaplan-Meier plots. The mean weight in kg and mean perioperative blood loss 
in ml are reported with SD or 95% CI and were analyzed with independent t-tests (parametric). 
Postoperative bleeding, infection, global satisfaction with treatment, impaired speech, and im-
paired swallowing are reported as number (n) and percent (%) and were analyzed with Fisher’s 
exact test (nonparametric). 
All data were analyzed with Stata 15 (StataCorp, USA). 
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3.4 PAPER IV – ADENOTONSILLECTOMY VS. WATCHFUL WAITING 
3.4.1 Design and study population 
This study was an RCT with two parallel arms comparing ATE with watchful waiting in chil-
dren, two to four years of age, with mild to moderate OSA. The recruitment process was the 
same as in Papers II and III (see chapter 3.3.1), and the inclusion/exclusion criteria were also 
the same, except from an OAHI of ≥ 2 and < 10 (mild OSA, OAHI ≥ 2 and < 5; moderate OSA, 
OAHI ≥ 5 and < 10). Both groups had a PSG and answered the OSA-18 questionnaire at base-
line and at the follow-up after six months. The PSG scorer was blinded to treatment allocation. 
The flow of participants is illustrated in Figure 9. 
The power analysis was calculated with an a level of 0.05 and 80% power. A difference of 2 
(2.5 SD) in OAHI change was used as the minimal clinically important difference between the 
groups. This generated required a study population of 52 children, but a total of 60 children 
were included in this study to compensate for dropouts and limitations in the power analysis. 
 
 
 
Figure 9 Flowchart Paper IV. Abbreviations: ATE, adenotonsillectomy; OSA, obstructive sleep apnea; PSG, poly-
somnography. 
 
PSG
(n = 388)
ATE
(n = 29)
Watchful waiting
(n = 31)
Children with symptoms of 
OSA
Dec 2014 - Dev 2017 
Dropouts
Discontinued intervention (n = 1)
Declined further participation (n = 2)
Postoperative PSG
(n = 28)
Excluded
Did not meet inclusion/exclusion criteria 
(n = 222) 
Declined to participate (n = 43)
Other reason (n = 63)
Postoperative PSG
(n = 25)
Randomization
(n = 60)
Dropouts
Did not receive intervention (n = 1)
Could not go through with PSG (n = 1)
Declined further participation (n = 2)
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3.4.2 Intervention 
The patient’s tonsils were removed by blunt extracapsular dissection, and the adenoid was re-
moved with coblation or a ring knife. 
 
3.4.3 Outcome measures 
The primary outcome was the difference in mean OAHI score change. Secondary outcomes 
were changes in other PSG variables, the OSA-18 questionnaire, the need for surgery because 
of residual OSA, and postoperative complications, such as infection and readmission due to 
bleeding. 
 
3.4.4 Statistical analyses 
The primary analysis was per protocol, but an ITT sensitivity analysis was also performed for 
the primary outcome of change in OAHI score. Missing values were imputed by multiple im-
putation. The statistical inference was performed by comparing effect sizes and 95% CI. 
The PSG variables were continuous data, and the results are given as the mean (SD) or as the 
mean (95% CI). Standardized effect sizes were calculated with the use of Cohen’s d, relating 
the magnitude of group difference to the standard deviation, and may be interpreted as follows: 
small, more than 0.20 to 0.49; medium, 0.50 to 0.79; and large, 0.80 or more. 
The OSA-18 questionnaire consisted of ordinal data and the results are given as the median 
(interquartile range), the median (95% CI, which is given with the Hodges–Lehmann estima-
tor), as well as a standardized effect size, Cohen’s d. 
Univariate associations were tested using logistic regression models to find factors that could 
predict an OAHI ≥ 2 and a total OSA-18 score ≥ 60 at follow-up. Variables that were consid-
ered predictive (p < 0.05) in the univariate analysis were included in a forward stepwise logistic 
multiple regression model. 
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4 RESULTS 
4.1 PAPER I – BLOOD PRESSURE AFTER MODIFIED UVULOPALATO-
PHARYNGOPLASTY 
A total of 71 patients were initially randomized for this study, but six patients deviated from 
the study protocol and were excluded. The remaining 65 patients were randomized to either 
UPPP (n = 32) or the control group (n = 33). The baseline characteristics were similar in both 
groups, and six patients had no documented blood pressure values at baseline (Table 2). 
 
Table 2 Baseline characteristics 
Parameter 
n 
Intervention 
group n 
Control 
group p 
Age (years) 32 41.7 (11.4) 33 42.9 (11.8) 0.662 
Sex (number and % of women) 32 4 (12.5%) 33 2 (6.1%) 0.370 
Body mass index (kg/m2) 32 28.2 (2.9) 33 27.7 (3.3) 0.519 
Apnea-Hypopnea Index (events/h sleep) 32 53.3 (19.7) 33 52.6 (21.7) 0.901 
Oxygen desaturation index (events/h sleep) 32 44.6 (23.5) 33 41.1 (22.2) 0.541 
Nadir O2 (%) 32 79.9 (5.3) 33 81.0 (6.6) 0.449 
Epworth Sleepiness Scale 32 12.5 (3.2) 33 12.9 (3.1) 0.631 
Systolic blood pressure (mmHg) 28 132.0 (15.9) 31 131.3 (16.5) 0.867 
Diastolic blood pressure (mmHg) 28 82.5 (10.9) 31 82.7 (10.9) 0.942 
Data are mean (SD), except for sex.      
 
At the six-month follow-up, the mean blood pressure had decreased in the UPPP group but not 
in the control group, and there were significant differences between the groups (SBP −9.4 
mmHg; 95% CI, −17.9 to −0.8; and DBP −6.4 mmHg; 95% CI, −12.8 to −0.04) (Table 3). In 
the sensitivity analysis, the UPPP group also had lower blood pressure values at the six-month 
follow-up, but the difference between the groups was not significant (SBP −5.3 mmHg; 95% 
CI, −13.6 to 2.7; and DBP −4.1 mmHg; 95% CI, −9.8 to 1.7). 
As mentioned, the mean (SD) blood pressure was unchanged in the control group at the six-
month follow-up. However, after the delayed surgery the blood pressure also decreased in the 
control group (n = 25/33), and the decrease in systolic blood pressure was significant (SBP 
−3.7 [8.8] mmHg, p < 0.05; and DBP −2.1 [6.9] mmHg, p = 0.14) (Figure 10). 
When analyzing all operated patients, there were significant decreases in both SBP and DBP 
after six months (n = 49, 75%) and 24 months (n = 35, 54%) (Table 4). Also, there were no 
change in mean BMI. However, 11 of the 65 operated patients were excluded due to changes 
in their antihypertensive treatment and the significant decrease in blood pressure was lost in 
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the sensitivity analysis. Further, there were significant correlations between the blood pressure 
and all the respiratory sleep parameters at the six-month follow-up. 
 
Table 3 Changes in blood pressure in the intervention and control group. 
 
Table 4 Blood pressure and body mass index for all operated patients at the 6-month and 24-month postoper-
ative follow-ups. 
 Preop (n=61/65) 
6 months 
postop 
(n=53/65) 
24 months 
postop 
(n=38/65) 
Preop compared to 
6 months postop 
(p) (n=49) 
Preop compared to 
24 months postop 
(p) (n=35) 
SBP (mmHg) 131.6 (16.8) 122.6 (14.3) 118.7 (15.9) 0.001 < 0.0001 
DBP (mmHg) 82.7 (11.5) 77.5 (11.3) 76.6 (11.1) 0.030 0.012 
BMI (kg/m2) 28.1 (3.4) 27.9 (3.3) 28.0 (3.4) 0.884 0.534 
Data are presented as mean (SD). P values from paired t-tests. Significant differences (p<0.05) are shown in bold 
type. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; n, num-
ber of patients. 
 
 
 
Figure 10 Blood pressure results for the UPPP and control group. Abbreviations: BL, baseline; 6m, six months; SBP, sys-
tolic blood pressure; DBP, diastolic blood pressure; UPPP, uvulopalatopharyngoplasty; n, number of patients. 
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Follow-up 
(n=33) 
p 
(n=31) 
Difference at fol-
low-up 
(95% CI) 
p 
(n=61) 
         
SBP 
(mmHg) 
132.0 (15.9) 121.8 (15.2) 0.011 131.3 (16.5) 131.2 (17.7) 0.793 -9.4 (-17.9, -0.8) 0.032 
DBP 
(mmHg) 
82.5 (10.9) 76.4 (12.6) 0.117 82.7 (10.9) 82.8 (12.2) 0.601 -6.4 (-12.8, -0.04) 0.049 
Data presented as mean (SD) or mean (95% CI). Group difference compared at the 6-month follow-up. P values from paired and unpaired 
t-tests. Significant differences (p<0.05) are shown in bold type. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; 
n, number of patients. 
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4.2 PAPER II – ADENOTONSILLECTOMY VS. ADENOPHARYNGOPLASTY 
A total of 83 children were randomly assigned to either APP (n = 36) or ATE (n = 47), and the 
groups were similar at baseline (Table 5). Four children in the ATE group and three children 
in the APP group were obese (BMI z-score ≥ 1.67). Of the 83 children, 44 (94%) in the ATE 
group completed the follow-up compared to 30 (83%) in the APP group. 
 
Table 5 Baseline characteristics. 
Parameter ATE (n = 47) 
APP 
(n = 36) 
Age at intervention, mean (SD), months 36.3 (9.7) 37.0 (8.7) 
Sex, No. (%)   
  Male 26 (55) 23 (64) 
  Female 21 (45) 13 (36) 
Length, mean (SD), cm 93.2 (6.6) 93.5 (6.6) 
Weight, mean (SD), kg 14.2 (2.6) 14.1 (2.8) 
BMI z-score, mean (SD) −0.08 (1.46) −0.20 (1.52) 
Tonsil sizea, median (IQR) 4 (3–4) 3.5 (3–4) 
Adenoid sizea, median (IQR) 3 (3–4) 3 (2–4) 
OAHI, mean (SD), events/hour of sleep 23.7 (11.5) 23.8 (11.5) 
Abbreviations: OAHI, Obstructive Apnea-Hypopnea Index; ATE, adenotonsillectomy; APP, adenopharyngoplasty. 
a Data are expressed as the median (interquartile range). Tonsil size scored according to Brodsky. Adenoid size scored according to 
occlusion (%) of the epipharynx: 1 = 0–25%, 2 = 25–50%, 3 = 50–75%, and 4 = 75–100%. 
 
All children had improved their OAHI scores at the follow-up, but one child in the ATE group 
still had severe OSA (OAHI = 27) at the follow-up compared to none in the APP group (Figure 
11). The ATE group had a mean decrease of 21.1 (88%; 95% CI 17.7 to 24.5), and the APP 
group had a mean decrease of 21.7 (91%; 95% CI 17.2 to 26.3). There was no significant dif-
ference between the groups (0.7; 95% CI −4.8 to 6.1). Moreover, the difference between the 
groups was also not significant in the ITT analysis (−1.6; 95% CI −7.3 to 4.0). 
Furthermore, statistical analyses found that there were no differences in other respiratory sleep 
parameters, success rates at different levels of postoperative OAHI, subgroup analyses for dif-
ferent preoperative OAHI and BMI z-scores, or OSA-18 scores (Tables 6 and 7). One patient 
in each group was readmitted due to postoperative bleeding, but no other complications were 
seen. 
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Figure 11 Boxplots and line graphs for the ATE and APP group. Boxplots: Boxes include the median and the first to third 
quartile. Whiskers are within the 1.5 interquartile range, and circles are outliers. Line graphs: Lines connecting individual 
pre- and postoperative OAHI scores. Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; OAHI, ob-
structive apnea-hypopnea index. 
 
 
Table 6 Success rate at different postoperative OAHI levels. 
OAHI 
Follow-up 
ATE 
(n = 44) 
APP 
(n = 30) p 
< 1 20% (9) 17% (5) 0.68 
< 2 48% (21) 50% (15) 0.85 
< 5 84% (37) 90% (27) 0.47 
< 10 98% (43) 100% (30) 0.41 
Rate of success, %, at a given postoperative OAHI level. The number of patients (n) is given within parentheses. Statis-
tical analysis with the test of proportions. Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; OAHI, 
obstructive apnea-hypopnea index. 
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Table 7 Polysomnography and OSA-18 results from baseline and the six-month postoperative follow-up. 
Parameters n 
ATE 
Baseline 
ATE 
Follow-
up p n 
APP 
Baseline 
APP 
Follow-
up p 
Difference 
in change 
between the 
groups 
(95% CI) p 
PSGa           
OAHI 44 23.8 (11.5) 2.8 (4.3) < 0.001 30 
23.8 
(11.8) 2.1 (1.7) < 0.001 
0.7 (−4.8 to 
6.1) 0.81 
Central AHI 42 2.7 (3.1) 2.0 (1.9) 0.17 30 2.9 (6.0) 1.9 (2.3) 0.36 0.3 (−1.7 to 2.4) 0.74 
REM AHI 40 51.1 (28.2) 6.5 (8.9) < 0.001 29 
42.5 
(28.1) 4.1 (3.5) < 0.001 
−6.2 (−20.1 to 
7.6) 0.37 
ODI 42 17.2 (11.0) 3.2 (2.8) < 0.001 30 
16.0 
(12.7) 2.7 (2.2) < 0.001 
−0.8 (−6.3 to 
4.8) 0.78 
RDI 42 24.1 (11.5) 3.0 (4.5) < 0.001 29 
23.8 
(11.7) 2.1 (1.7) < 0.001 
0.6 (−5.0 to 
6.3) 0.82 
Mean Sat O2, 
% 42 96.6 (0.8) 97.0 (0.8) 0.01 30 96.7 (0.9) 97 (0.7) 0.20 
0.2 (−0.4 to 
0.7) 0.51 
Nadir O2, % 41 83.4 (6.8) 89.4 (4.3) < 0.001 29 83.6 (8.2) 88.3 (4.5) 0.002 1.3 (−2.4 to 5.0) 0.49 
Total Sleep 
Time, min 41 454 (38) 457 (33) 0.60 29 460 (41) 458 (37) 0.77 
5.7 (−14.6 to 
25.9) 0.58 
Sleep Effi-
ciency, % 41 93 (6) 95 (4) 0.14 29 93 (5) 92 (6) 0.38 
3.2 (−0.7 to 
7.1) 0.11 
OSA-18b           
Total Symp-
tom Score 40 
63 
(49–78) 
28.5 
(26–39.5) < 0.001 29 
67 
(57–78) 
30 
(26–42) < 0.001 
−0.5 (−13 to 
12) 0.64 
Sleep Disturb-
ance Index 40 
18.5 
(16–23.5) 
5 
(4–6.5) < 0.001 29 
18 
(16–23) 
6 
(4–8) < 0.001 −2 (−6 to 2) 0.28 
HRQoL 39 7 (4–8) 9 (8–10) < 0.001 27 7 (4–8) 9 (8–10) < 0.001 0 (−1 to 1) 0.91 
Abbreviations: PSG, polysomnography; ATE, adenotonsillectomy; APP, adenopharyngoplasty; OAHI, obstructive apnea-hypopnea in-
dex; REM AHI, rapid eye movement apnea-hypopnea index; ODI, oxygen desaturation index; RDI, respiratory distress index; Mean Sat 
O2, mean oxygen saturation; Nadir O2, oxygen saturation nadir; HRQoL, health-related quality of life; n, number of patients. Significant 
differences are marked in bold (p < 0.05). 
aPSG data are expressed as mean (SD) and are analyzed with parametric tests (paired and unpaired t-tests). 
bOSA-18 scores and HRQL are expressed as median (interquartile range) and are analyzed with non-parametric tests (Wilcoxon signed-
rank test and Mann–Whitney U-test). 
 
4.3 PAPER III – POSTOPERATIVE MORBIDITY AFTER ADENOTONSILL-
ECTOMY VS. ADENOPHARYNGOPLASTY 
A total of 64 out of 83 (77%) patients returned the logbook; 39 (83%) of these patients were in 
the ATE group, and 25 (69%) were in the APP group. Sixty-five (78%) patients answered the 
questionnaire regarding bleeding, infection, satisfaction with treatment, speech, and swallow-
ing; in this subset were 38 (81%) patients from the ATE group and 27 (75%) patients from the 
APP group. Data regarding postoperative infection and peri- and postoperative bleeding were 
obtained for all children through medical records. 
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Table 8 Pain-related outcomes for adenotonsillectomy versus adenopharyngoplasty. 
Parameter n ATE n APP p 
First day when child estimates pain = 0 (FPS-R) 33 7 (6–10) 22 9 (7 to >10) 0.018 
First day when child estimates pain < 6 (FPS-R) 32 2 (1–7) 22 4 (1–10) 0.117 
First day when caregiver estimates pain = 1 (VAS) 39 7 (6–10) 25 8 (7–10) 0.548 
First day when caregiver estimates pain ≤ 5 (VAS) 38 3 (1–7) 25 3 (1–7) 0.657 
First day without analgesics 39 9 (8–10) 25 8 (8–10) 0.798 
First day with return to normal diet 39 7 (6–9) 25 8 (7 to >10) 0.111 
Weight change (kg) 35 0.0 (0.6) 22 0.1 (0.5) 0.273 
Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; FPS-R, Faces Pain Scale – Revised; VAS, visual 
analogue scale; kg, kilograms; n, number of patients. 
 
Data are expressed as median, with interquartile range, and the groups are compared with log-rank tests, except for weight 
change. The weight change is expressed as mean, with standard deviations, and the groups are compared with an independ-
ent t-test. 
 
Statistical analysis determined that there was a significant difference regarding the first day 
that the children graded themselves as pain free (FPS-R = 0). Median day (interquartile range) 
was 7 (6 to 10) in the ATE group, compared with 9 (7 to > 10) in the APP group (p = 0.018). 
There were no significant differences in mean weight change (−0.2 kg; 95% CI −0.5 to 0.1) or 
in any other pain-related outcomes (Table 8) (Figure 12). 
Additionally, there were no significant differences regarding other outcomes of bleeding, in-
fection, satisfaction with treatment, speech, and swallowing. However, three children in the 
APP group reported worse speech compared to none in the ATE group (p = 0.067) (Table 9). 
 
Table 9 Bleeding and other postoperative outcomes for adenotonsillectomy versus adenopharyngoplasty. 
Parameter n ATE n APP pa 
Perioperative bleeding, ml (SD) 47 34 (17) 36 37 (21) 0.5075 
Postoperative bleeding, n (%) 47 1 (2) 36 1 (3) 1.000 
Postoperative infection, n (%) 47 0 (0) 36 1 (3) 0.434 
Impaired swallowing, n (%) 36 1 (3) 24 0 (0) 1.000 
Impaired speech, n (%) 38 0 (0) 27 3 (11) 0.067 
Abbreviations: ATE, adenotonsillectomy; APP, adenopharyngoplasty; n, number; SD, standard deviation; ml, milliliter. 
a The groups were compared with Fisher’s exact test; however, the mean perioperative bleeding (ml) was analyzed with an 
independent t-test. 
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Figure 12 a–f Kaplan-Meier plots for six pain-related outcomes in both groups. P-values for group comparison with log-
rank tests. ATE, adenotonsillectomy; and APP, adenopharyngoplasty. 
 
4.4 PAPER IV – ADENOTONSILLECTOMY VS. WATCHFUL WAITING 
A total of 60 children were randomly assigned to either ATE (n = 29) or watchful waiting (n = 
31), and 53 of the children (88%) completed the study; 25 (86%) in the ATE group and 28 
(90%) in the watchful waiting group. The groups were similar at baseline (Table 10). One child 
in the ATE group and three in the watchful waiting group were obese (BMI z-score ≥ 1.67). 
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Table 10 Baseline characteristics 
Parameter ATE (n = 29) 
Watchful waiting 
(n = 31) 
Age at first PSG, mean (SD), months 39 (8) 37 (11) 
Sex, No. (%)   
Male 15 (52) 19 (61) 
Female 14 (48) 12 (39) 
BMI z-score, mean (SD) 0.2 (1.4)a 0.2 (1.1) 
Tonsil sizeb, median (IQR) 3 (3–3) 3 (2–3) 
OAHI, mean (SD), events/hour of sleep 4.9 (1.9) 5.0 (2.2) 
OSA severity, n (%)c   
Mild OSA 15 (52) 16 (52) 
Moderate OSA 14 (48) 15 (48) 
Total OSA-18 score, median (IQR)d 59 (49–74) 58.5 (48–69) 
< 60, n (%) 14 (50) 17 (57) 
60 to 80, n (%) 10 (36) 10 (33) 
> 80, n (%) 4 (14) 3 (10) 
Abbreviations: ATE, adenotonsillectomy; OAHI, Obstructive Apnea-Hypopnea Index; OSA, obstructive sleep apnea. 
a One missing value in the ATE group (n = 28). 
b Tonsil size scored according to Brodsky (scored according to occlusion (%) of the oropharynx: 1, 0–25%; 2, 26–50%; 
3, 51–75%; and 4, 76–100%). 
c Mild OSA, OAHI ≥ 2 and < 5; Moderate OSA, OAHI ≥ 5 and < 10. 
d One missing value in each group; ATE group = 28 and watchful waiting group = 30. 
 
Both groups showed a statistically significant reduction in mean OAHI score at the follow-up 
in the per protocol analysis. The ATE group had a mean OAHI score decrease of −2.9 (95% 
CI −4.0 to −1.9; Cohen’s d = −1.14), the watchful waiting group had a mean decrease of −1.9 
(95% CI −3.0 to −0.9; Cohen’s d = −0.71). The difference between the groups was small and 
not statistically significant (−1.0; 95% CI −2.4 to 0.5; Cohen’s d = −0.37). The result was sim-
ilarly non-significant in the ITT analysis (−1.0; 95% CI −2.3 to 0.3; Cohen’s d = −0.38; n = 
60). Further, there were no or small differences between the groups in other PSG variables 
(Table 11), and ATE had slightly better success rates, but the difference was not statistically 
significant (Table 12). 
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Table 11 Polysomnography, OSA-18, and VAS QoL results from baseline to follow-up. 
 
 
 ATE  Watchful waiting  
Group 
difference  
Parametersa n 
 
Base-
line 
Change at 
follow-up 
(95% CI) 
Effect 
sizeb n 
Base-
line 
Change at 
follow-up 
(95% CI) 
Effect 
sizeb 
Difference 
in change 
(95% CI) 
Effect 
sizeb 
           
OAHI 25 4.8 
(1.9) 
-2.9 (-4.0 -
1.9) 
-1.14 28 5.1 
(2.2) 
-1.9 (-3.0 to -
0.9) 
-0.71 -1.0 (-2.4 to 
0.5) 
-0.37 
Central AHI 24 1.7 
(1.6) 
-0.5 (-1.2 to 
0.3) 
-0.26 25 2.1 
(2.2) 
-0.5 (-1.2 to 
0.2) 
-0.32 0.1 (-0.9 to 
1.1) 
0.03 
ODI3% 25 3.0 
(2.5) 
-0.4 (-1.3 to 
0.5) 
-0.20 27 3.7 
(2.6) 
-1.0 (-1.9 to -
0.1) 
-0.44 0.5 (-0.7 to 
1.7) 
0.24 
Mean Sat O2, 
% 
25 97.2 
(1.0) 
-0.3 (-0.7 to 
0.1) 
-0.31 27 97.0 
(0.7) 
-0.2 (-0.4 to 
0.1) 
-0.29 -0.1 (-0.6 to 
0.3) 
-0.16 
Nadir O2, % 24 89.6 
(3.7) 
0.2 (-1.7 to 
2.0) 
0.04 27 88.0 
(5.5) 
-0.1 (-3.2 to 
3.0) 
-0.01 0.2 (-3.4 to 
3.9) 
0.04 
Sleep Effi-
ciency, % 
25 91.7 
(5.9) 
2.0 (-1.4 to 
5.4) 
0.24 26 93.6 
(6.0) 
0.1 (-3.7 to 
3.9) 
0.01 1.9 (-3.1 to 
6.9) 
0.22 
Sleep stage 1, 
%c 
25 1.7 
(1.9) 
-0.3 (-1.4 to 
0.7) 
-0.13 26 2.1 
(2.2) 
-1.1 (-2.1 to -
0.1) 
-0.43 -0.7 (-0.7 to 
2.2) 
0.30 
Sleep stage 2, 
%c 
25 23.4 
(12.4) 
1.6 (-3.7 to 
6.9) 
0.12 26 30.7 
(12.5) 
-7.1 (-14.1 to 
-0.1) 
-0.13 8.7 (0.1 to 
17.4) 
0.57 
Sleep stage 
3-4, %c 
25 56.9 
(14.2) 
0.0 (-6.5 to 
6.6) 
0.00 26 49.0 
(14.3) 
7.3 (-0.1 to 
14.6) 
0.40 -7.2 (-16.9 to 
2.4) 
-0.42 
Sleep stage 
REM, %c 
25 18.0 
(5.5) 
-1.3 (-4.2 to 
1.6) 
-0.19 26 18.1 
(5.0) 
1.0 (-1.2 to 
3.1) 
0.18 -2.3 (-5.8 to 
1.2) 
-0.37 
           
Total OSA-
18 Score 
23 57 (48–
74) 
-23.5 
(-31.5 to -
15) 
-1.24 26 56.5 
(48–
70) 
-4.5 (-12 to 
1.5) 
-0.36 -17 (-24 to -
10) 
-0.97 
Sleep Dis-
turbance 
Score 
23 15 (11–
18) 
-7 (-8.5 to -
4.5) 
-1.39 26 15 
(12–
16) 
-0 .5(-2.5 to 
1) 
-0.13 -6 (-9 to -4) -1.23 
VAS QoL 24 6.5 (5–
9) 
1.5 
(0.5 to 3) 
0.72 24 7 (4.5 
to 8.5) 
0.5 (-0.5 to 2) 0.25 1 (0 to 2) 0.40 
Abbreviations: ATE, adenotonsillectomy; OAHI, obstructive apnea-hypopnea index; ODI3%, oxygen desaturation in-
dex; Mean Sat O2, mean oxygen saturation; Nadir O2, oxygen saturation nadir; QoL, quality of life; VAS, visual ana-
logue scale; CI, confidence interval; n, number of patients. 
a Polysomnography data is expressed as mean (SD). OSA-18 scores and VAS QoL are expressed as median (interquar-
tile range). 
b Effect sizes were calculated with the use of Cohen’s d, relating the magnitude of group difference to the standard de-
viation, and may be interpreted as follows: small, more than 0.20 to 0.49; medium, 0.50 to 0.79; and large, 0.80 or 
more. 
c % of total sleep time. 
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Table 12 Success rate at different levels of OAHI at follow-up. 
OAHI at follow-up ATE (n = 25) 
Watchful waiting 
(n = 28) 
Difference 
(95% CI) 
< 1 36 (9) 25 (7) 11 (−14 to 36) 
< 2 60 (15) 50 (14) 10 (−17 to 37) 
< 5 96 (24) 82 (23) 14 (−2 to 30) 
The results for each group are given as % (n). Abbreviations: ATE, adenotonsillectomy; OAHI, obstructive apnea-hy-
popnea index; and n, number of patients. 
Z-test of two proportions was used when comparing different levels of success. 
 
Two children in the ATE group had an increased OAHI score at the follow-up, compared to 
four in the watchful waiting group. Also, two children with moderate OSA in the watchful 
waiting group had developed severe OSA (Figure 13). At baseline, 11 children in the ATE 
group (mean OAHI score 6.5; SD 1.2) and 13 children in the watchful waiting group (mean 
OAHI score 7.1; SD 1.1) had moderate OSA. Subgroup analyses on children with moderate 
OSA showed a meaningful and statistically significant group difference with a mean OAHI 
score change of −3.1 (95% CI −5.7 to −0.5; Cohen’s d = −1.00) in favor of ATE. On the other 
hand, for the subset of children with mild OSA, the difference in the OAHI score was 0.7 (95% 
CI −0.5 to 1.9; Cohen’s d = 0.42), which was small and statistically non-significant. 
There were large improvements in total OSA-18 score (−23.5; 95% CI −31.5 to −15; Cohen’s 
d = −1.24) in the ATE group, but there were only small improvements in the watchful waiting 
group. The difference between the groups was large, clinically meaningful, and statistically 
significant (Table 11). Upon follow up, all 23 (100%) children in the ATE group had a total 
OSA-18 score of less than 60. In the watchful waiting group, 20 (76%) children had a total 
OSA-18 score of less than 60, five (19%) had a score between 60-80, and one (4%) had a score 
over 80.  
In the watchful waiting group, 10 of 28 (36%) children received ATE after the follow-up due 
to persistent symptoms. Of these children, seven (70%) had moderate OSA at baseline, and 
two (20%) still had an OAHI score of 2 or more at the postoperative follow-up. One patient in 
the ATE group was readmitted due to postoperative bleeding, but no other complications were 
observed. 
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Figure 13 Boxplots and line graphs that illustrates the obstructive apnea-hypopnea index scores (OAHI) for adenotonsil-
lectomy (ATE) (A) and watchful waiting (B) at baseline and follow-up. Boxplots: Boxes include the median and the first 
to third quartile. Whiskers are within the 1.5 interquartile range, and circles are outliers. Line graphs: Lines connecting 
individual OAHI scores. 
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5 DISCUSSION 
5.1 RANDOMIZED CONTROLLED TRIAL 
There are several different types of study designs, but RCTs are considered the best design for 
evaluating cause-effect relationships between a treatment and an outcome. While both re-
searchers and study participants can affect the results through selection bias, the randomization 
process balances both known and unknown characteristics between study groups; this is not 
possible with other study designs. Additionally, if the randomization is successful, an RCT is 
the best way to remove the effect of regression to the mean. To further decrease bias, the par-
ticipants and researchers, if possible, can be blinded for treatment allocation, as this prevents 
preconceived views to systematically bias the treatment assessment. Further, to prevent manip-
ulation of the results, an RCT should have a pre-specified primary outcome and be registered 
in a clinical trials database. 
Although RCTs are powerful tools for evaluating various treatment effects, there are limitations 
to their applicability. For instance, it may not be ethical to randomly select participants for a 
treatment that is believed to be inferior. RCTs are also not suitable for studies about rare dis-
eases, for which it can be difficult to recruit participants. Finally, RCTs are time consuming 
and have high costs. Despite these limitations, there is a need for well-designed RCTs, when 
suitable, in order to improve the evidence-based treatment for OSA. 
 
5.2 PAPER I – DOES SURGICAL TREATMENT FOR OBSTRUCTIVE SLEEP 
APNEA ALSO IMPROVE THE BLOOD PRESSURE? 
Although UPPP was the primary treatment for adult OSA before the introduction of CPAP, the 
effect of UPPP on the patient’s blood pressure is less understood. The effect of CPAP and 
MRDs on blood pressure has been widely studied, but the effect seems to be modest. System-
atic reviews have only shown a decrease of 2.6 to 2.7 mmHg in SBP and 2.0 to 2.7 mmHg in 
DBP61–63. Other studies142–144 have shown that sleep surgery may have a positive effect on 
blood pressure and other cardiovascular endpoints, but the evaluation of these relationships is 
difficult because there is no standard surgical procedure to treat OSA in adults. The overall 
evidence for improvement in cardiovascular endpoints after surgical treatment is weak, and, 
thus, there is a need for RCTs66. 
In an RCT that studied the effect of UPPP on blood pressure in adults with OSA (Paper I), we 
found that blood pressure significantly decreased six months after surgery; the SBP decreased 
by 9.4 mmHg, and the DBP decreased by 6.4 mmHg. The control group also experienced a 
significant decrease in blood pressure six months after surgery. Furthermore, there were sig-
nificant correlations between respiratory sleep parameters and blood pressure, which further 
indicated a beneficial treatment effect. The decrease in blood pressure was still significant after 
two years. Weight loss, which is another important factor in treating adult OSA, did not seem 
to affect the result, as the mean BMI was unchanged.  
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The combined results from this study and the original SKUP3 study45 suggest that modified 
UPPP has a positive effect on respiratory sleep parameters, QoL, and blood pressure. This is 
important to address, as both OSA and hypertension are major health concerns and may be 
lifelong conditions, and other treatments, such as CPAP, MRDs, and antihypertensives, suffer 
from poor patient compliance37–39,41,145. If untreated, patients with OSA face a higher risk for 
cardiovascular mortality and other serious disorders5. Therefore, modified UPPP should be 
considered in selected cases where CPAP or MRDs fail. 
 
5.2.1 Limitations 
The results of this study must be interpreted with caution, as the sensitivity analyses showed 
neither significant differences between the groups nor improvements in all operated patients. 
There was a high risk for attrition bias related to the exclusion of patients with changes in 
antihypertensive treatment and a high proportion of missing values (46%) at the follow up after 
two years. Furthermore, this study was small and was not primarily designed to evaluate blood 
pressure; hypertension, antihypertensive treatment, and blood pressure were not part of any 
inclusion or exclusion criteria. However, there were no differences between the groups regard-
ing these cardiovascular factors at baseline. The blood pressure measurement protocol in this 
study was also a limiting factor. While blood pressure was taken manually and only once in the 
morning after a PSG, a 24-hour ambulatory blood pressure would have been preferable, since 
blood pressure fluctuates over time. Additionally, smoking, exercise, and other comorbidities 
that can affect blood pressure were not controlled for during this study. 
 
5.3 PAPERS II AND III – IS ADENOPHARYNGOPLASTY BETTER THAN 
ADENOTONSILLECTOMY? 
Surgery is the primary treatment for OSA in children, as adenotonsillar hypertrophy is the ma-
jor risk factor. ATE is the most common surgical procedure for OSA in children worldwide, 
although adenotonsillotomy is becoming more popular. However, residual OSA after surgery 
is not uncommon and more frequent in children with obesity, severe OSA, and genetic, crani-
ofacial, and neurological disorders. Various surgical procedures have been investigated to im-
prove the surgical outcome. For instance, APP is believed to reduce the obstruction of the upper 
airway by closure of the tonsillar pillars after ATE. Previous studies of APP have shown prom-
ising results regarding respiratory sleep parameters and QoL, but further research is 
needed125,126. Moreover, previous work has shown contradicting results regarding postopera-
tive morbidity, such as pain and postoperative bleeding125,146–148. 
An RCT was developed to evaluate the efficacy of APP over ATE for otherwise healthy chil-
dren with severe OSA. The findings of this study were reported in Papers II and III. In Paper 
II no significant differences were found regarding changes in the OAHI, other respiratory sleep 
parameters, or QoL. The APP group had a large reduction in mean OAHI of 91%, but the ATE 
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group had a reduction of 88%, and the difference between the groups was small. The non-
significant difference between the groups could not be explained by an unexpectedly high re-
duction in OAHI after ATE, since the results for ATE are similar to those of other studies with 
comparable preoperative values115,118. Furthermore, previous studies that indicate that APP is 
more effective than ATE are not convincing. For instance, in the small prospective study from 
Chiu et al.126 (n = 24), the groups were not randomized and not similar at baseline, which could 
explain the better effect after APP. Nevertheless, while Friedman et al.125 (n = 60) conducted 
an RCT and have suggested there might be a difference between APP and ATE, their results 
were not statistically significant. This might be explained by a high dropout rate (27%), ren-
dering the Friedman et al. study underpowered. Their study was also limited by the fact that 
only 25% of the children were evaluated with PSG. 
In Paper II no differences in QoL, as measured with OSA-18, between the two groups were 
observed, while Friedman et al.125 found a difference in QoL in favor of APP. However, the 
groups in the Friedman et al. study were already different at baseline, which likely explains the 
significant difference at follow-up. 
Friedman et al.125 could not show a statistically significant difference between the groups in 
postoperative pain, which was measured by return to normal diet and activity. While there are 
reports that covering the tonsillar fossa after ATE could affect the postoperative pain and the 
risk for postoperative bleeding, the results are not consistent125,146–149. In Paper III, postoper-
ative morbidity, such as postoperative pain, bleeding, infection, satisfaction with treatment, and 
impaired speech and swallowing, was evaluated. The results regarding pain were slightly in 
favor of ATE, but the only statistically significant difference in outcome was for when the 
children scored themselves as pain free (FPS-R = 0). There were no significant differences in 
any other pain-related outcomes, such as pain reported by the caregivers, weight change, num-
ber of days with analgesics, or when the children returned to normal diet. However, the results 
from the FPS-R must be interpreted with caution, as the FPS-R is validated and recommended 
for children from four years of age141, and 80% of the children who responded to the logbook 
were less than four years of age. Nevertheless, Borgström et al.150 conducted an RCT compar-
ing ATE with ATT that used the same methodology as in Paper III for a similar group of chil-
dren. In the Borgström et al. study, children scored themselves as pain free eight days after 
ATE, which is similar to the seven days reported in Paper III. The combined results from all 
pain-related outcomes in Paper III were slightly in favor of ATE. 
It is difficult to compare these pain-related outcomes with other studies due to differences in 
methodology. For instance, there is an extensive RCT by Matt et al.146 (n = 763) in which the 
tonsillar pillars were closed after ATE on one side and left open on the other side, effectively 
making the pediatric patients their own controls. Matt et al. have reported that the children felt 
more pain after APP compared to ATE. The number of patients included is a strength of the 
study, but to evaluate two different methods in the same patient is difficult, especially in young 
children. The results in Paper III are more comparable with the results from two smaller stud-
ies with similar design, surgical techniques, and outcomes. Friedman et al.125, as mentioned 
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earlier, did not report a difference between when the two groups returned to normal diet or 
activity, and an RCT by Fornazieri et al.(n = 132)147 found neither a difference in return to 
normal diet nor in pain that was self-reported using a faces pain scale. Even so, Paper III 
suffers from a small sample size and no well-defined clinically important differences regarding 
the outcomes.  
One patient in each group was readmitted due to postoperative bleeding, but the sample size 
was too small in order to draw any conclusions. Larger studies are contradictory on this matter. 
Matt et al.146 showed no difference in postoperative bleeding, but a retrospective study by Sen-
ska et al.148 (n = 2000) reported that the need for second surgery due to bleeding after APP was 
almost halved compared to after ATE. These differences may be explained by several factors, 
such as surgical technique and study design. 
Swallowing and speech disorders after APP are not well documented but are well-reported in 
adults who have received UPPP151. While the sample size in Paper III was too small to yield 
conclusive results, three children reported impaired speech after APP compared to none after 
ATE. The difference was not statistically significant (p = 0.067), but probably of clinical inter-
est, and should be studied further with validated methods.  
In summary, the results from Papers II and III did not show any certain clinically important 
differences between APP and ATE regarding respiratory sleep parameters, postoperative mor-
bidity, or QoL. However, APP is a more extended method and therefore ATE should still be 
considered as the primary treatment for otherwise healthy children with severe OSA. 
 
5.3.1 Limitations 
There are several limitations in Papers II and III that should be considered. First, there was a 
skewed distribution (n = 47 for ATE and n = 36 for APP), which probably can be explained by 
a logistical error – i.e. the sealed randomization envelopes were not taken in order from the 
stack. Even so, the groups were similar at baseline, and there were enough children in each 
group according to the power analysis. Although obesity is a risk factor for persistent OSA, the 
results are not generalizable for obese children because there were only a few obese patients 
included in this study. Furthermore, the power was probably not sufficient in order to show any 
statistically significant differences regarding postoperative morbidity. Also, the FPS-R is not 
validated for children below four years of age, and the questionnaire regarding speech and 
swallowing was not validated. However, these outcomes are generally difficult to study in 
young children, and these tools were used in the absence of other validated methods. 
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5.4 PAPER IV – SHOULD ALL CHILDREN WITH OBSTRUCTIVE SLEEP 
APNEA RECEIVE SURGERY? 
Obstructive sleep apnea is a common disorder in children, and ATE is overall one of the most 
frequent surgical treatment methods in children. Previous reports have shown that ATE is ef-
fective at improving QoL and respiratory sleep parameters128,152, but children can also improve 
without treatment. For instance, in CHAT113, a large RCT (n = 464) by Marcus et al., ATE was 
compared to watchful waiting in children with mild to moderate OSA. The study was not de-
signed to primarily study the effect of treatment on respiratory sleep parameters, but the results 
showed significant improvements in OAHI and QoL after ATE compared to after watchful 
waiting. Nevertheless, as many as 46% of the children in the watchful waiting group achieved 
normal sleep parameters (OAHI <2) by the follow-up, and children with a lower OAHI at base-
line had a higher degree of normalization. These results suggest that watchful waiting could be 
an alternative for children with mild OSA. However, the children in the CHAT study were 
between five and nine years of age. The effect of watchful waiting in children between two and 
four years of age is still unknown according to a review by Cochrane128, and there is a need for 
RCTs that evaluate the effect in these children. It is important to study children in this age 
group, as they have the highest prevalence of OSA and are the primary recipients of surgery. 
Thus, peri- and postoperative risks must be considered. 
In Paper IV, ATE was compared to watchful waiting in children between two and four years 
of age. This study found significant improvements in mean OAHI score change within both 
groups, but the difference between the groups was small and not statistically significant (−1.0; 
95% CI −2.4 to 0.5). A similar result (−0.98) was found in a recent RCT known as the Preschool 
Obstructive Sleep Apnea Tonsillectomy and Adenoidectomy (POSTA) study153 (n = 190), 
which compared ATE with watchful waiting in children between three and five years of age 
with a baseline mean OAHI of 1.9. Although the difference in OAHI between the patient 
groups in POSTA was statistically significant, the study was designed to evaluate cognition 
rather than respiratory sleep parameters, and, therefore, the result may not reflect a clinically 
relevant difference. The statistical significance can probably be explained by a large study sam-
ple. However, it is difficult to define a clinically relevant group difference in OAHI scores, as 
there are no well-established and predetermined values. In the present study, which was de-
signed to study changes in OAHI, a group difference of 2, which we believed would be of 
clinical value for this group of children, was defined as clinically relevant. Although the dif-
ference in mean OAHI between the groups was small (−1.0) and not significant, the result is 
not totally conclusive, as the confidence interval (95% CI −2.4 to 0.5) does not exclude a dif-
ference of 2 between the groups. However, children with moderate OSA seemed to have a 
larger and statistically significant improvement after ATE compared to after watchful waiting. 
As this is a subgroup analysis, the results should be interpreted with caution; nevertheless, the 
CHAT113 study arrived at the same conclusion. Further and larger studies are needed to confirm 
these results. 
Why some children improve without treatment is not well understood, but lower OAHI, smaller 
waist circumference, and absence of obesity may increase the chance of spontaneous 
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improvement.154 This was partly confirmed in Paper IV, where a lower baseline OAHI was 
also found to be a predictor for OSA resolution (OAHI <2) after watchful waiting. However, 
other factors, such as wider airways due to growth, regression to the mean and night-to-night 
variability, should also be taken into consideration. 
Although PSG is the gold standard method to diagnose OSA, there are no strong correlations 
between improvements in respiratory sleep parameters and changes in QoL99–102. Even mild 
OSA has been shown to have a large impact on QoL155, which indicates that PSG is not perfect 
in measuring all aspects of OSA and might miss improvements that are important for children 
with OSA. QoL is a crucial health outcome measure, and, therefore, it is of importance to con-
sider both PSG outcomes as well as QoL to properly treat children with OSA. This study found 
large improvements in OSA-18 scores after ATE, which is consistent with findings in other 
RCTs99,129,156. The difference between the groups was also large and relevant, in favor of ATE, 
and agrees with the result in CHAT113. 
To summarize, the combined results from Paper IV and other studies suggest that otherwise 
healthy children, two to four years of age, with moderate OSA should be recommended ATE. 
This supports the recommendations for OSA treatment in children from the European Respir-
atory Society127. However, children with mild OSA and low impact on QoL might benefit from 
a period of watchful waiting. Even so, larger studies are needed to confirm these results. 
 
5.4.1 Limitations 
This study has several limitations. First, it was a small study (n = 60). It primarily included 
otherwise healthy children, so the results are not applicable to children with obesity, comorbid-
ities or severe OSA. Additionally, the study was not blinded for children and caregivers, so the 
differences in QoL may be explained by a surgical placebo effect. The choice to evaluate chil-
dren with both mild and moderate OSA might be questioned, but this design was selected to 
enable comparison to the CHAT study. Furthermore, PSG is in general not used, and it is dif-
ficult to distinguish between mild and moderate OSA using only history and clinical examina-
tion.  
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6 CONCLUSIONS 
The results from the studies included in this thesis suggested that: 
Paper I Blood pressure decreased significantly six months after modified UPPP in a 
selected group of adult patients with moderate to severe OSA. The effect was 
maintained two years after surgery, but more uncertain due to a high proportion 
of missing values. 
 
Paper II APP was not more effective than ATE at improving respiratory sleep parameters 
or QoL in otherwise healthy children with severe OSA. 
 
Paper III ATE was slightly favored over APP regarding postoperative morbidity (e.g. pain, 
bleeding, infection, satisfaction with treatment, speech, and swallowing). The 
combined results from Papers II and III suggested that ATE should still be 
considered as the primary treatment for otherwise healthy children with severe 
OSA. 
 
Paper IV Otherwise healthy children with moderate OSA did benefit from early ATE, and 
a period of watchful waiting could be an alternative for children with mild OSA 
and a low impact on QoL. 
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7 ETHICAL CONSIDERATIONS 
In all scientific research, ethical considerations must be made regarding the autonomy, integ-
rity, quality, as well as the risks and benefits of the research. 
Autonomy was considered for the studies reported in Papers II, II, and IV, in which young 
children were patients. The children were not capable of making an informed decision of 
whether or not to participate in the study, and thus their autonomy was compromised. However, 
written informed consent was attained from the caregivers, who were believed to be generally 
good representatives of the children's interests. The children approached for the study received 
proper treatment regardless of whether they ultimately participated in the study or not. Addi-
tionally, no economic compensation was provided that could have caused caregivers to disre-
gard the children's interests. In Paper I all participants were adult, and the patient’s autonomy 
was not considered to be compromised. All adult patients provided an informed consent, re-
ceived treatment regardless of study participation, and received no economic compensations. 
A considerable amount of sensitive personal data were handled in these studies. To protect the 
integrity of all study participants, the data was handled unidentified. All personal information 
was kept in a locked and safe place that was inaccessible to unauthorized persons. 
The quality of the research is another ethical aspect to take into consideration. Low quality 
research does not generate new or increased knowledge, wastes resources, and exposes study 
participants to unnecessary risks and time-consuming procedures. Although the studies de-
scribed in this thesis did not have large sample sizes, they were of high quality for several 
reasons. Importantly, all studies were RCTs, which have a high scientific value and are unusual 
in surgical treatment studies. PSG was used, which is the gold standard method to diagnose 
and evaluate OSA. The study samples were based on power calculations and there were low 
dropout rates. The participants and caregivers were blinded if possible and the PSG scorers 
were blinded in all studies. Finally, the studies were requested. 
Risks and benefits of the studies was also considered. Surgery always comes with risks, such 
as pain, bleeding, and infection. In Paper IV, some children with mild symptoms may have 
been unnecessarily exposed to surgical risks, but they would have been offered surgery regard-
less of study participation. In Papers II and III, the children received APP, which is not a 
standard treatment method and might be associated with higher risks, but previous studies have 
not shown any obvious negative side effects or complications. In Paper I, the adult patients 
were not exposed to any extra surgical risks, as they also would have been offered surgery 
regardless of study participation. Furthermore, one might argue that patients in the control 
groups in Papers I and IV experienced the risks associated with untreated OSA. However, the 
follow-up time was short, no children with severe OSA were affected, and both children and 
adults were offered surgery if their OSA symptoms clinically worsened during the follow-up 
period or if they still had OSA after the follow-up. Additionally, at the start of SKUP3 in 2007, 
surgery for adult OSA was questioned. It was not obvious that adult patients should be offered 
surgery rather than be left untreated if they had failed treatment with CPAP and MRD. Thus, 
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despite the risks, we believe that the benefits of these studies exceeded the risks. We also be-
lieve that the results of these studies have increased the knowledge of surgical treatment of 
OSA, helped clinicians ensure that patients do not receive surgery unnecessarily, and helped 
patients with OSA to receive the correct surgical treatment.  
All papers have been reviewed by an ethical board. The study in Paper I was approved by the 
Central Ethics Board (ref Ö21-2007), after first being rejected by the Swedish Regional Ethics 
Board, Stockholm (ref 2007/449-31/3). The studies in Papers II, II, and IV were approved by 
the Swedish Regional Ethics Board, Stockholm (ref 2014/1000-31/1). 
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8 FUTURE PERSPECTIVES 
Sleep medicine research is performed all over the world to understand more about sleep and its 
important impact on our lives. However, increased knowledge leads to more questions and 
there are still a lot of questions to be answered in this vast research field. 
OSA is a major health problem with increased risk for cardiovascular mortality, and there is a 
need for more studies that evaluate the effect on cardiovascular endpoints after surgery. Related 
to the research in Paper I, there is a need for larger RCTs that record the 24-hour ambulatory 
blood pressure and other surrogate markers, such as blood lipids and systemic inflammatory 
markers. Blood samples collected during SKUP3 are being analyzed by our research team and 
will provide further knowledge about these surrogate markers. 
Although APP was not shown to be a superior treatment option to ATE in Papers II and III, 
there are still questions to be answered. The results from Papers II and III are only general-
izable to otherwise healthy children with severe OSA. Persistent OSA has been observed in 
some patients after ATE, and further studies in children with other risk factors, such as obesity 
and Down syndrome, would be of interest. 
An important factor to consider is the discrepancy between PSG and subjective outcomes. In 
Paper IV, no differences were found in respiratory sleep parameters between the ATE and 
watchful waiting groups, but large differences in QoL were observed. Although PSG is gold 
standard, the correlation between respiratory sleep parameters, symptoms, behavior and QoL 
needs to be better understood to better define clinically relevant improvements in respiratory 
sleep parameters. 
The results in Paper IV suggested that children with mild OSA could benefit from a period of 
watchful waiting. There are also studies indicating that anti-inflammatory drugs (e.g. intranasal 
steroids and leukotriene receptor antagonist) could improve both QoL and respiratory sleep 
parameters. Further studies with medical treatment would be of interest to confirm the efficacy 
and long-term results. 
In general, there is a need for long-term follow-ups. Three- and ten-year follow-ups are planned 
for the patients who participated in the studies described in Papers II, II, and IV. Blood sam-
ples and tonsillar tissue from these pediatric patients have been saved. Hopefully, these samples 
can be analyzed to better understand the etiology of tonsillar growth and potentially lead to 
new and improved medical treatments.  
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Obstruktiv sömnapné (OSA) är vanligt hos både vuxna och barn. Tillståndet karaktäriseras av 
obstruktiva andningsuppehåll, vilket orsakas av trängsel i den övre luftvägen. Andningsuppe-
hållen leder till upphackad sömn med störd sömnkvalitet och perioder med syrebrist. Hos 
vuxna kan detta exempelvis leda till uttalad dagtrötthet, högt blodtryck och ökad dödlighet i 
hjärt-kärlsjukdomar, medan det hos barn kan leda till påverkad tillväxt, inlärningssvårigheter 
och beteendestörningar. 
Hos vuxna beror OSA främst på övervikt, men manligt kön, rökning och stigande ålder är också 
exempel på andra kända riskfaktorer. Förstahandsbehandlingen är CPAP (Continuous Positive 
Airway Pressure), men svalgkirurgi kan också vara ett alternativ i väl utvalda fall. Även om 
CPAP har visat sig vara effektivt för att behandla andningsuppehållen är effekten sparsam när 
det gäller att förbättra blodtrycket. Hur blodtrycket påverkas efter svalgkirurgi är dock mindre 
känt och detta utvärderades i delarbete I. 
Hos barn orsakas främst trängseln i de övre luftvägarna av förstorade tonsiller (halsmandlar) 
och adenoid (körtel bakom näsan). Kirurgi är den primära behandlingen och traditionellt utförs 
adenotonsillektomi (ATE), vilket innebär att tonsillerna och adenoiden avlägsnas. Det är en 
beprövad metod med goda resultat, men en del barn har kvarvarande besvär. Övervikt och 
allvarlig OSA är exempel på riskfaktorer för kvarvarande OSA efter kirurgi. Det finns dock 
studier på barn som indikerar att adenopharyngoplastik (APP), vilket är en modifierad form av 
ATE där även de främre och bakre gombågarna sys ihop, förbättrar behandlingsresultaten. APP 
utvärderades i delarbete II och III. Utöver kirurgisk behandling har exspektans även varit 
klinisk rutin i lindriga fall, då det av klinisk erfarenhet och studier finns chans till spontan för-
bättring. Trots att det är vanligt att barn yngre än fem år opereras för OSA saknades randomi-
serade studier som bekräftar nyttan av operation för denna åldersgrupp. Detta utvärderades i 
delarbete IV. 
Inom forskning finns det olika typer av studiedesign, men för att dra slutsatser om behand-
lingseffekt anses randomiserade kontrollerade studier (RCT) vara de med högst bevisvärde. 
Det övergripande målet med de fyra delarbetena i denna avhandling var att med hjälp av RCT 
utvärdera och utöka kunskapen om kirurgisk behandling av barn och vuxna med OSA. 
Delarbete I var en RCT på vuxna, där effekten på blodtrycket utvärderades efter modifierad 
uvulopalatopharyngoplastik (UPPP), vilket är en form av svalgkirurgi. I denna studie lottades 
65 patienter till antingen UPPP eller till en obehandlad kontrollgrupp. Blodtrycket mättes ma-
nuellt direkt på morgonen i samband med varje sömnundersökning. Resultatet visade att grup-
pen som opererats hade förbättrat sitt blodtryck jämfört med kontrollgruppen efter sex måna-
der. Efter den första uppföljningen erhöll även kontrollgruppen UPPP och intressant nog för-
bättrades även kontrollgruppen efter att de erhållit kirurgi. Blodtrycket var fortsatt förbättrat 
två år efter operation för alla opererade patienter, men bortfallet var stort och resultatet måste 
tolkas med försiktighet. 
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Delarbete II och III var en RCT på 83 barn med grav OSA, i åldern två till fyra år. I denna 
studie lottades barnen till APP eller ATE, och följdes upp efter sex månader. De fick utföra 
polysomnografi (PSG), vilket är en sömnundersökning som anses vara den bästa metoden för 
att diagnosticera OSA, samt svara på olika frågeformulär. I delarbete II utvärderades resulta-
ten från sömnundersökningen och OSA-18, ett livskvalitetsformulär. Båda grupperna förbätt-
rades och APP visade sig inte vara mer effektivt än ATE gällande att minska andningsuppe-
hållen eller förbättra livskvaliteten. I delarbete III utvärderades huruvida det fanns någon skill-
nad gällande smärta, infektion, blödning, tal- och sväljningssvårigheter samt nöjdhet efter op-
eration. Detta bedömdes med hjälp av smärtdagbok, frågeformulär och journalanteckningar. 
Smärtdagboken fylldes i under tio dagar direkt efter operationen. Resultaten visade väldigt små 
skillnader mellan grupperna, men till fördel för ATE. De kombinerade resultaten från delar-
bete II och III visar att APP inte är mer fördelaktigt än den traditionella metoden ATE. Därmed 
bör ATE fortfarande betraktas som den primära behandlingen för annars friska barn med grav 
OSA. 
Delarbete IV var en RCT på 60 barn i åldern två till fyra år med mild till måttlig OSA. De 
lottades till ATE eller ingen behandling, och utvärderades med polysomnografi och OSA-18. 
De följdes upp efter sex månader och resultaten visade på små skillnader, med avseende på 
sömnundersökningen. Däremot visade resultaten att barn med måttliga besvär från början hade 
en bättre effekt av kirurgi än de med milda besvär. Det var också stora skillnader i förbättrad 
livskvalitet mellan grupperna till förmån för ATE. Dessa resultat tyder på att barn med måttlig 
OSA bör erhålla ATE direkt, medan det kan vara en fördel att avvakta med behandling under 
en period hos barn med god livskvalitet och mild OSA.  
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